AstraZeneca announced the construction of a cell‑therapy manufacturing and innovation centre in Shanghai, establishing the first global drugmaker with end‑to‑end cell‑therapy capabilities in China.
The Shanghai complex will support the development, production, and distribution of cell‑therapy products, including CAR‑T therapies and the dual‑acting cell therapy AZD0120 acquired through Gracell Biotechnologies. The facility is part of a $15 billion pledge to invest in China through 2030.
The new site will complement the company’s Virginia manufacturing plant and other U.S. investments, underscoring a global strategy to build a resilient supply chain for advanced therapies.
By establishing a full‑cycle platform in Shanghai, AstraZeneca aims to accelerate its pipeline and meet growing demand for advanced biologics in the Chinese market, leveraging the country’s large patient population and biopharmaceutical ecosystem.
The announcement signals a strategic pivot toward cell‑therapy, aligning with the company’s broader investment in cell‑therapy infrastructure and the integration of the Gracell acquisition.
"As one of China’s leading biopharmaceutical hubs, Shanghai has established a robust pathway from foundational research and R&D translation to advanced manufacturing, fostering a vibrant innovation ecosystem." – Iskra Reic, Executive Vice President of International
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.